title: Are Synthetic Compounds that Silence the Liver-X-Receptor the Next Generation of Anti-cancer Drugs?
abstract: Glycolytic and lipogenic inhibitors have proven unsuccessful in cancer treatment strategies. In this issue of Cancer Cell, Flaveny and colleagues target the liver-X-receptor with an inverse agonist and show that key glycolytic and lipogenic genes are suppressed, leading to apoptosis of tumor cells without an effect on non-malignant cells.
authors.affiliation: Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. Electronic address: knut.steffensen@ki.se.
authors.forename: Knut R
authors.initials: KR
authors.lastname: Steffensen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D050155:Lipogenesis / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy*; D057093:Orphan Nuclear Receptors / Q000819:agonists*; D054852:Small Molecule Libraries / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D057093:Orphan Nuclear Receptors; D054852:Small Molecule Libraries; D013449:Sulfonamides